Previous close | 11.10 |
Open | 11.34 |
Bid | 10.75 x 200 |
Ask | 10.81 x 200 |
Day's range | 10.74 - 11.61 |
52-week range | 1.33 - 11.61 |
Volume | |
Avg. volume | 334,377 |
Market cap | 512.599M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.05 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.75 |
Performance Showcases Strategic Advancements Amid Financial Challenges
Shattuck Labs (STTK) delivered earnings and revenue surprises of 21.28% and 457.50%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June – - Randomized, controlled Phase 1B dose-expansion cohort in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients expected to initiate enrollment in the second quarter of 2024 – - Presented preclinical data at the 2024 A